RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $217.00. The ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other stocks. While stocks ...

Analysts fell to the sidelines weighing in on Biogen (BIIB – Research Report) and Sanofi (SNY – Research Report) with neutral ratings, ...